Combination Therapies and New Molecular Targets—Presentations from AACR 2021

Conference Correspondent —June 19, 2021

Categories:

AACR & ASCO 2021 - Midyear Review
David R. Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.
Related Articles
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent
Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing.
Exciting New Data Presented on NSCLC at AACR 2021
David R. Spigel, MD
|
Conference Correspondent
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC.
Practice-Changing Data in NSCLC from ASCO 2021
Mark A. Socinski, MD
|
Conference Correspondent
Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC.
Last modified: June 22, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Country
     
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2021 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512